Search research articles
Contact Us
Filters
Showing results (51-60 of 195) with videos related to
Page
of 20
Sort By:
American Journal of Hematology
|
May 20, 2016
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
Neil P Shah, Philippe Rousselot, Charles Schiffer, et al.
Oncotarget
|
October 17, 2015
Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia
Heriberto Bruzzoni-Giovanelli, Juan R González, François Sigaux, et al.
Research and Practice in Thrombosis and Haemostasis
|
September 23, 2024
Evaluation of hemostasis understanding in medical and pharmacy students from a Parisian university
Nicolas Gendron, Dominique Helley, Philippe Rousselot, et al.
American Journal of Hematology
|
September 19, 2012
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study
Philippe Rousselot, Pascale Cony-Makhoul, Franck Nicolini, et al.
British Journal of Haematology
|
July 20, 2004
Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires
Danielle Canioni, Pauline Brice, Eric Lepage, et al.
Journal of Internal Medicine
|
July 10, 2023
Novel precision medicine approaches and treatment strategies in hematological malignancies
Richard Rosenquist, Elsa Bernard, Tom Erkers, et al.
Blood
|
September 16, 2006
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot, Francoise Huguet, Delphine Rea, et al.
Molecular Biology Reports
|
August 12, 2021
KMT2A-ARHGEF12, a therapy related fusion with poor prognosis
Nada Assaf, Raphael Liévin, Fatiha Merabet, et al.
International Journal of Cancer
|
April 21, 2009
NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants
Nadia Lounnas, Catherine Frelin, Nadège Gonthier, et al.
Haematologica
|
August 11, 2018
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
Timothy P Hughes, Pierre Laneuville, Philippe Rousselot, et al.
Page
of 20
Search research articles
Search
Showing results (51-60 of 195) with videos related to
Sort By:
Page
of 20
American Journal of Hematology
|
May 20, 2016
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
Neil P Shah, Philippe Rousselot, Charles Schiffer, et al.
Oncotarget
|
October 17, 2015
Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia
Heriberto Bruzzoni-Giovanelli, Juan R González, François Sigaux, et al.
Research and Practice in Thrombosis and Haemostasis
|
September 23, 2024
Evaluation of hemostasis understanding in medical and pharmacy students from a Parisian university
Nicolas Gendron, Dominique Helley, Philippe Rousselot, et al.
American Journal of Hematology
|
September 19, 2012
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study
Philippe Rousselot, Pascale Cony-Makhoul, Franck Nicolini, et al.
British Journal of Haematology
|
July 20, 2004
Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires
Danielle Canioni, Pauline Brice, Eric Lepage, et al.
Journal of Internal Medicine
|
July 10, 2023
Novel precision medicine approaches and treatment strategies in hematological malignancies
Richard Rosenquist, Elsa Bernard, Tom Erkers, et al.
Blood
|
September 16, 2006
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot, Francoise Huguet, Delphine Rea, et al.
Molecular Biology Reports
|
August 12, 2021
KMT2A-ARHGEF12, a therapy related fusion with poor prognosis
Nada Assaf, Raphael Liévin, Fatiha Merabet, et al.
International Journal of Cancer
|
April 21, 2009
NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants
Nadia Lounnas, Catherine Frelin, Nadège Gonthier, et al.
Haematologica
|
August 11, 2018
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
Timothy P Hughes, Pierre Laneuville, Philippe Rousselot, et al.
Page
of 20